Format

Send to

Choose Destination
See comment in PubMed Commons below
Exp Cell Res. 2009 Feb 15;315(4):649-58. doi: 10.1016/j.yexcr.2008.07.031. Epub 2008 Aug 15.

The ErbB kinase domain: structural perspectives into kinase activation and inhibition.

Author information

1
Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. rbose@dom.wustl.edu

Abstract

Epidermal growth factor receptor (EGFR) and its family members, ErbB2, ErbB3 and ErbB4, are receptor tyrosine kinases which send signals into the cell to regulate many critical processes including development, tissue homeostasis, and tumorigenesis. Central to the signaling of these receptors is their intracellular kinase domain, which is activated by ligand-induced dimerization of the receptor and phosphorylates several tyrosine residues in the C-terminal tail. The phosphorylated tail then recruits other signaling molecules and relays the signal to downstream pathways. A model of the autoinhibition, activation and feedback inhibition mechanisms for the ErbB kinase domain has emerged from a number of recent structural studies. Meanwhile, recent clinical studies have revealed the relationship between specific ErbB kinase mutations and the responsiveness to kinase inhibitor drugs. We will review these regulation mechanisms of the ErbB kinase domain, and discuss the binding specificity of kinase inhibitors and the effects of kinase domain mutations found in cancer patients from a structural perspective.

PMID:
18761339
PMCID:
PMC2668223
DOI:
10.1016/j.yexcr.2008.07.031
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center